Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.74 |
| ▸ | CASP7 | P55210 | 1/20 | 0.74 |
| ▸ | CASP6 | P55212 | 1/20 | 0.74 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.74 |
| ▸ | TERT | O14746 | 14/20 | 0.71 |
| ▸ | PTPRC | P08575 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629661 | 1.00 | CASP3 (0.74) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL13663715 | 0.94 | PTPRC (0.74) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL4293006 | 0.90 | CASP3 (0.75) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL11633144 | 0.90 | CASP3 (0.75) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL4298269 | 0.87 | PTPRC (0.83) | TERTPTPRC | |
| SCHEMBL4294197 | 0.86 | CASP3 (0.72) | CASP3TERT | |
| SCHEMBL31237670 | 0.86 | CASP3 (0.72) | CASP3TERT | |
| SCHEMBL9630631 | 0.86 | CASP3 (0.72) | CASP3TERT | |
| SCHEMBL15427156 | 0.82 | ALDH1A1 (0.72) | CASP3TERTPTPRC | |
| SCHEMBL3382902 | 0.81 | ALDH1A1 (0.70) | CASP3TERTPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| WO-1998025884-A1 | FURTHER ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | TERT, NAT10, POT1 | CASP3 916/4885CASP2 1408/4885CASP7 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.